Source comparison
Pharmacokinetic Profile: Acute Hormone Release Versus Chronic Adaptation
CJC-1295 No DAC differs fundamentally from its long-acting analogue (CJC-1295 with DAC, also called DAC:GRF) in plasma half-life and dosing frequency. The 'No DAC' variant lacks the Drug Affinity Complex modification. Specifically, the maleimidoproprionic acid
This comparison does not assign a generated winner or score.
- CJC-1295 No DAC differs fundamentally from its long-acting analogue (CJC-1295 with DAC, also called DAC:GRF) in plasma half-life and dosing frequency. The 'No DAC' variant lacks the Drug Affinity Complex modification. Specifically, the maleimidoproprionic acid linker that binds serum albumin. Resulting in rapid clearance within 2–4 hours post-injection. This necessitates multiple daily administrations (typically 2–3 times daily in research protocols) to sustain elevated GH exposure across a 24-hour period.
- Ipamorelin exhibits a similarly short half-life (approximately 2 hours), with GH elevation peaking 30–60 minutes post-dose and returning to baseline by 3–4 hours. The synergy between CJC-1295 No DAC and ipamorelin lies in their complementary receptor mechanisms: GHRH receptor activation (CJC-1295) combined with ghrelin receptor agonism (ipamorelin) produces GH pulse amplitudes 3–5 times greater than baseline, without the cortisol or prolactin elevation seen with earlier-generation secretagogues like GHRP-6 or hexarelin.
- Research demonstrating this timeline: a 2006 study published in the Journal of Clinical Endocrinology & Metabolism measured plasma GH levels in healthy adults following single-dose administration of modified GRF(1-29). The base structure of CJC-1295 No DAC. Peak GH concentrations occurred at 45 minutes, with levels returning to baseline by 180 minutes. When combined with a ghrelin mimetic in animal models, the amplitude increased significantly, but the duration remained constrained by peptide clearance rates.
- The practical implication: researchers measuring immediate GH response can quantify peptide activity within hours. Those investigating downstream endpoints. IGF-1 upregulation, nitrogen retention in muscle tissue cultures, lipolysis in adipocyte models. Must design protocols spanning weeks to months.